Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes - Trial NCT06403761
Access comprehensive clinical trial information for NCT06403761 through Pure Global AI's free database. This Phase 1 trial is sponsored by Novo Nordisk A/S and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 150 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
Phase 1
May 06, 2024
Dec 18, 2025
Primary Outcome
To compare the effect of CagriSema versus placebo: Change in M-value in hyperinsulinaemic euglycaemic clamp (HEC)
Summary
This study will look at how CagriSema, semaglutide and cagrilintide regulate insulin effects
 in the body of people with type 2 diabetes (T2D). CagriSema is a new investigational medicine
 that combines two medicines called cagrilintide and semaglutide. Doctors may not yet
 prescribe CagriSema. Participants will either get CagriSema, semaglutide, cagrilintide, or a
 ''dummy'' medicine. Which treatment the participants will get is decided by chance.
 Participants will get the study medicine together with the current daily diabetes medicine
 metformin. Participants should not take other medicines for diabetes during the study. The
 study will last for about 42 weeks.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06403761
Non-Device Trial